Waldsassen/Munich. BioVariance GmbH, which is located in Waldsassen, took an important strategic step regarding the future orientation of the company by admitting two new partners. At the beginning of the year FlemingEnterprise Holding GmbH, Nuremberg, and Blaugold Investment GmbH, Munich, supported BioVariance GmbH with a medium seven-digit amount in exchange for a minority shareholding. With the provided capital Josef Scheiber, founder and managing director of BioVariance GmbH, wants to achieve company growth in the field of applied precision medicine. The focus is on the improvement of the sales structure and the international market access as well as the further development of existing and new products and services, including an app for patients and physicians.
The admission of the new investors is accompanied by the commencing cooperation with Oberender AG, a management consulting company located in Bayreuth and Munich. Managers and consultants of Oberender AG will support the development and implementation of required measures for the internationalisation of BioVariance, the product development and the professionalisation of the distribution. The consulting in regulatory framework, e.g. regarding the german payers, is another key factor. Since last summer there have been discussions about the cooperation opportunities.
BioVariance GmbH is a bioinformatics company founded in 2013 and located in Waldsassen. 17 employees analyse and interpret complex biomedical data and thus identify biological signatures of patients. These results allow an individual adjustment of the medication in e. g. oncologic or psychiatric indications.